Target Discovery

By combining proprietary adenoviral technology with complex cellular assays, Charles River’s target discovery group has delivered numerous novel, validated drug targets in a range of therapeutic areas. We examine the effects of introducing shRNAs (SilenceSelect®) or full-length cDNAs (FLeXSelect®) contained within our libraries of adenoviruses into human primary cells, differentiated stem cells or cell lines. siRNA and miRNA technologies are also available for gene knockdown studies. Advanced readouts, such as high-content screening and high-throughput gene expression analysis, are used to measure the effects of knockdown and thus identify the genes that have an effect on a disease-relevant pathway.

Capabilities

You may also be interested in...